MDR-reversing 8-hydroxy-quinoline derivatives
US10744127B2 · kind B2 · utility
0Cited by
1References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 5, 2017 |
| Grant date | Aug 18, 2020 |
| Priority date | — |
| Expiry date | Apr 5, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is related to 8-hydroxy-quinoline derivatives having multidrug-resistance reversing activity with improved selectivity and increased cytotoxicity towards multidrug-resistant cancer cells, preparation thereof and use of the same in the treatment of cancer, especially multidrug-resistant variants thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.